SLC5A2 and chronic kidney disease: SGLT2/1 inhibition was associated with a 4 mmHg lower systolic BP at 1 year and reductions in dead nephron count and albuminuria (−28% and −8%, respectively), as compared to untreated CKD (Figure 8).